The roles of macromolecules in imatinib resistance of chronic myeloid leukemia cells by Fourier transform infrared spectroscopy
Loading...

Date
2013
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier France-editions Scientifiques Medicales Elsevier
Open Access Color
Gold
Green Open Access
Yes
OpenAIRE Downloads
120
OpenAIRE Views
74
Publicly Funded
No
Abstract
Imatinib is a first generation tyrosine kinase inhibitor, which is used for the treatment of chronic myeloid leukemia. However, resistance to imatinib is an important problem. Different mechanisms have been explained for imatinib resistance. In this study, we examined the roles of macromolecules in imatinib resistance in K562 cells at the molecular level using Fourier Transform Infrared (FT-IR) spectroscopy. An amount of 3 mu M imatinib resistant cells were generated by our group and named as K562/IMA-3 cells. Changes in macromolecules in parental and resistant cells were studied by FT-IR spectroscopy. Imatinib resistance caused changes, which indicated decreases in the level of glycogen and increases in the membrane order. The amount of unsaturated lipids increased in the imatinib resistant cells indicating lipid peroxidation. Imatinib resistance caused changes in the lipid/protein ratio. The relative protein content increased with respect to nucleic acids indicating higher transcription and protein expression and structural/organizational changes in the nucleus were evident as revealed by frequency changes in the nucleic acid bands. Changes in the amide bands revealed changes in the proteome of the resistant cells. Protein secondary structural changes indicated that the antiparallel beta sheet's structure increased, however the alpha helix structure, beta sheet structure, random coil structure and turns decreased in the resistant cells. These results indicate that the FT-IR technique provides a suitable method for analyzing drug resistance related structural changes in leukemia and other cancer types. (C) 2013 Elsevier Masson SAS. All rights reserved.
Description
Baran, Yusuf/0000-0002-1056-4673
ORCID
Keywords
Imatinib, Chronic myeloid leukemia, Multidrug resistance, Fourier transform infrared spectroscopy, Macromolecular Substances, Antineoplastic Agents, Piperazines, Pyrimidines, Drug Resistance, Neoplasm, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Benzamides, Spectroscopy, Fourier Transform Infrared, Imatinib Mesylate, Humans, K562 Cells
Fields of Science
0301 basic medicine, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis
Citation
12
WoS Q
Q1
Scopus Q
Q1

OpenCitations Citation Count
12
Source
Biomedicine & Pharmacotherapy
Volume
67
Issue
3
Start Page
End Page
PlumX Metrics
Citations
CrossRef : 7
Scopus : 13
PubMed : 3
Captures
Mendeley Readers : 24

